One-year safety of sirukumab monotherapy: results from a randomized, double-blind, parallel-group, multicenter study in Japanese subjects with moderate to severe rheumatoid arthritis [abstract]

Authors
Category Primary study
Year 2015
This article has no abstract
Epistemonikos ID: ff7a7ce7e5e55f5b4ca83a7c63f5a74530186439
First added on: Sep 09, 2018